Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Declines By 15.7%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 101,800 shares, a decline of 15.7% from the November 15th total of 120,700 shares. Based on an average daily volume of 451,500 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the company’s stock are short sold.

Aptose Biosciences Price Performance

APTO stock remained flat at $0.19 during midday trading on Friday. 301,482 shares of the company’s stock were exchanged, compared to its average volume of 306,369. The stock’s 50 day simple moving average is $0.31 and its 200-day simple moving average is $0.50. The firm has a market capitalization of $11.61 million, a price-to-earnings ratio of -0.06 and a beta of 1.06. Aptose Biosciences has a 1 year low of $0.13 and a 1 year high of $2.68.

Analysts Set New Price Targets

A number of analysts have commented on the stock. StockNews.com started coverage on shares of Aptose Biosciences in a research note on Sunday. They issued a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.